Immuron Limited (AU:IMC) has released an update.
Immuron Limited, an Australian biopharmaceutical company, will feature CEO Steven Lydeamore presenting at the Peak Biotech Showcase in Melbourne. The company specializes in oral immunotherapies such as Travelan®, which aims to prevent travelers’ diarrhea. Immuron is also advancing IMM-529, a treatment for Clostridioides difficile infection, showing promise in pre-clinical trials.
For further insights into AU:IMC stock, check out TipRanks’ Stock Analysis page.
